Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 5 million to RMB 10 million, aimed at implementing equity incentives or employee stock ownership plans [1][4][6]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 5 million and RMB 10 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 30 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6]. - The repurchase will be conducted through the Shanghai Stock Exchange's trading system [1][5]. - The duration for the repurchase is within 12 months from the board's approval date [1][4]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for implementing equity incentives or employee stock ownership plans [1][4][8]. - If the company fails to implement these plans within three years after the repurchase, the unutilized shares will be canceled [1][4][12]. Shareholder and Management Plans - Major shareholders, including the actual controller and board members, have no plans to reduce their holdings in the next three to six months [2][10][11]. - The proposal for the repurchase was initiated by the actual controller and chairman, Mr. Cao Lin, based on confidence in the company's future development [12][13]. Financial Impact and Structure Changes - As of March 31, 2025, the company's total assets were RMB 5.266 billion, with net assets attributable to shareholders at RMB 3.901 billion [8]. - The repurchase amount, if at the upper limit of RMB 10 million, would represent approximately 0.02% of total assets and 0.26% of net assets [8]. - The repurchase is expected to have no significant impact on the company's operations, financial status, or future development [8]. Compliance and Authorization - The repurchase plan has been approved by more than two-thirds of the board members and does not require shareholder meeting approval [3][4]. - The management is authorized to handle all matters related to the repurchase, including adjustments to the plan as necessary [13][14].

【品大事】 海正药业：拟投资成立合成生物学合资公司 海正药业公告，公司拟与全资子公司瀚晖制药之香港全资子公司辉正国际合资设立合成生物学独立子公 司，注册资本3.5亿元。海正药业拟认缴出资2.6亿元，占74.29%，辉正国际拟认缴出资0.9亿元。合资公 司将整合资源，提升决策效率，为公司合成生物学业务发展提供支撑。 金种子酒：公司经营范围不存在变更主业情况 金种子酒发布澄清公告称，公司近日关注到有关媒体发布题为《经营范围删除"白酒"，金种子酒要转 型？》，《金种子酒不做白酒了？》等相关报道，公司现就相关情况予以澄清说明。公司原经营范 围"白酒和其他酒生产"系公司1998年上市以来在工商登记系统填报信息，没有发生过变更。为使用市场 监管总局统一的《经营范围规范表述目录（试行）》开展经营范围登记规范化工作，根据市场监督管理 局要求，公司现有的经营范围表述需同步变更为《经营范围规范表述目录（试行）》中对应的规范表 述，为适应工商登记分类变化，公司对经营范围进行相应规范调整，由"白酒和其他酒生产"变更为"酒 制品生产"，公司经营范围不存在变更主业情况，未来公司将继续聚焦资源，做优做强白酒主业。 6月19日晚间，沪深两市 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-027 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交易 方式回购部分公司已发行的人民币普通股（A 股），回购方案具体如下： ● 回购股份金额：人民币 500 万元（含）至 1,000 万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：用于实施股权激励或员工持股计划。若公司未能在股份回购完 成之后 3 年内实施股权激励或员工持股计划，未实施部分的股份将依法予以注销。 ● 回购股份价格：不超过人民币 30 元/股（含），该价格不高于公司董事会通过回 购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：通过上海证券交易所交易系统以集中竞价交易方式回购。 ● 回购股份期限：自董事会审议通过本次回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划： 1、公司 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-028 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交易 方式回购部分公司已发行的人民币普通股（A 股），回购方案具体如下： ● 回购股份金额：人民币 500 万元（含）至 1,000 万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：用于实施股权激励或员工持股计划。若公司未能在股份回购完 成之后 3 年内实施股权激励或员工持股计划，未实施部分的股份将依法予以注销。 ● 回购股份价格：不超过人民币 30 元/股（含），该价格不高于公司董事会通过回 购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：通过上海证券交易所交易系统以集中竞价交易方式回购。 ● 回购股份期限：自董事会审议通过本次回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划： 1、公司控 ...

Core Viewpoint - The company plans to repurchase shares with a budget of 5 million to 10 million yuan, with a maximum repurchase price of 30 yuan per share, aimed at implementing equity incentives or employee stock ownership plans [1] Summary by Categories Share Repurchase Plan - The company intends to repurchase between 166,700 to 333,300 shares, which represents 0.04% to 0.08% of the total share capital [1] - The repurchase period is set for 12 months from the date of board approval, with funding sourced from the company's own funds [1] Stakeholder Commitment - The company's controlling shareholder, actual controller, and board members have no plans to reduce their holdings in the next 3 to 6 months [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-026 南京诺唯赞生物科技股份有限公司 关于公司董事长兼总经理、实际控制人 提议回购公司股份的提示公告 （一）回购股份的种类及回购方式：以集中竞价交易方式回购公司已发行的 人民币普通股（A 股）。 （二）回购股份的用途：用于股权激励或员工持股计划。若公司未能在股份 回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使用的已回 购股份将予以注销。如国家相关政策调整，则回购方案按调整后的政策实行。 （三）回购股份的期限：自公司董事会审议通过回购方案之日起 12 个月内。 （四）回购股份的价格：不超过人民币 30 元/股（含）。 （五）回购股份的资金总额：不低于人民币 500 万元（含），不超过人民币 1,000 万元（含）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 17 日收到公司董事长兼总经理、实际控制人曹林先生递交的《关于提议南京诺唯赞 生物科技股份有限公司回购公司 ...

诺唯赞公告，公司董事长兼总经理、实际控制人曹林提议以集中竞价交易方式回购公司股份，回购资金 总额为500万元-1000万元，回购价格不超过人民币30元/股，回购股份用于股权激励或员工持股计划。 若未能在回购实施结果暨股份变动公告日后3年内使用完毕，尚未使用的回购股份将予以注销。提议人 在提议前6个月内未买卖公司股份，并承诺在董事会上对回购议案投赞成票。 ...

Core Insights - The article highlights the rise of domestic biological reagents in China, which have historically relied on imports, as the industry undergoes significant transformation due to the growth of the pharmaceutical and health sectors [1][2] - Nanjing Novozan Biotechnology Co., Ltd. has established a self-controlled technology platform, overcoming key technical challenges in high-end enzymes and antibodies, thereby enhancing China's biopharmaceutical supply chain [1][2][3] Industry Overview - Biological reagents, including enzymes and antibodies, are essential for research and development in life sciences, diagnostics, and vaccine production, often referred to as the "chip" of life sciences [1] - The industry has seen a shift as domestic companies like Novozan gain ground against foreign competitors, particularly in high-end reagent markets [1][2] Company Development - Founded in 2012, Novozan began its journey to develop localized biological reagents, addressing issues such as high costs and long delivery times associated with imported products [2][3] - The company has achieved significant breakthroughs in key technologies, enabling it to produce a range of over 1,000 types of recombinant enzymes and 3,000 types of high-performance antigens and monoclonal antibodies [5][6] Product Innovation - Novozan successfully developed a domestic high-sensitivity troponin test for early diagnosis of myocardial infarction, which is priced at 60% of the imported equivalent and delivers results in just 8 minutes [3][4] - The company is focusing on Alzheimer's disease (AD) blood testing, with products already in use in over 100 top-tier hospitals and third-party testing institutions [5][6] Marketing Strategy - Novozan's marketing approach for AD testing emphasizes a comprehensive service ecosystem that integrates technology development, clinical application, and academic outreach, rather than just product sales [6][7] - The company aims to enhance public awareness of AD and provide tailored solutions to medical institutions, establishing strategic partnerships to create a complete diagnostic and treatment ecosystem [6][7] International Expansion - Novozan has begun exporting products, including NGS (Next Generation Sequencing) reagents, to international markets, marking a significant step in its global strategy [8][9] - The company has established warehouses in key regions such as North America, Europe, and Southeast Asia to improve delivery times, reducing the product delivery cycle from 40-50 days to as little as 3 days [10]

【SynBioCon】 获 悉，近日， 诺泰生物 （688076.SH）与 诺唯赞生物 （688105.SH）战略签约，合作 成立合资公司，共同推进双方在 合成生物学领域 的业务发展。 这是诺泰生物在小分子技术平台，多肽技术平台和寡核苷酸技术平台的基础上，拓展建设的 合成生物学技 术平台 。公司高度重视科技平台的建设和创新，通过学科交叉推行平台战略，实现产业升级，扩大公司在 医药产品的技术和生产优势，巩固和提升在细分领域的领先地位。 此次战略合作的达成，不仅是诺泰生物（688076.SH）与诺唯赞生物（688105.SH）在业务拓展和技术创新 方面的重要一步，也为整个生物科技行业带来了新的发展机遇。期待双方未来在合成生物学领域内的探索 不仅能在生物医药领域产生重大影响力，还可以在 动物保健 与 农业 等更多领域产能较强的影响力。 合资 公司由诺泰生物控股 。 生物合成是生物学研究的前沿领域，以生物酶作为催化剂为核心。与传统化学反应相比， 生物酶催化展现 出诸多显著优势，如绿色无害、安全性高、特异性极强以及原子经济性高等。 （ Source: 《生物革命：创新改变了经济、社会和人们的生活——麦肯锡全球研究院》（ ...

Market Overview - The Shanghai Composite Index closed at 3399.77 points, above the six-month moving average, with a gain of 0.43% [1] - The total trading volume of A-shares reached 13126.55 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 220 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 8.76% deviation, closing price at 14.00 yuan, with a daily gain of 16.86% and turnover rate of 21.88% [1] - Haochen Medical: 8.62% deviation, closing price at 3.12 yuan, with a daily gain of 9.86% and turnover rate of 7.25% [1] - Guangyun Technology: 8.13% deviation, closing price at 14.22 yuan, with a daily gain of 9.89% and turnover rate of 6.59% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - CITIC Special Steel: minor deviation, closing price at 20.30 yuan, with a daily gain of 10.69% [1] - Nanda Optoelectronics: minor deviation, closing price at 36.44 yuan, with a daily gain of 9.99% [1] -沃尔核材: minor deviation, closing price at 25.41 yuan, with a daily gain of 11.75% [1]